Aktis Starts Phase 1b Trial for Nectin-4 Radiotherapy Drug
May 28, 2025
AKY-1189 is a potential first-in-class novel Nectin-4 targeted radiopharmaceutical product candidate that has previously demonstrated substantial tumor uptake across several solid tumor types Aktis Oncology,